Supplement: The Treatments

The Treatments ARTICLE EXTRAS A Troubled History First-Generation Antipsychotic Drugs The Atypical Atypical? The next generation? The Lessons of CATIE Second-Generation Antipsychotic Drugs Beyond Drugs Nonmedication Therapies When you add up the direct costs of treating patients with schizophrenia, it is a staggering number: $22 billion in the United States alone. As effective as many of them are, antipsychotic drugs are costly, and many have signific

Written byThe Scientist
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

A Troubled History

First-Generation Antipsychotic Drugs

The Atypical Atypical?

The next generation?

The Lessons of CATIE

Second-Generation Antipsychotic Drugs

Beyond Drugs

Nonmedication Therapies

When you add up the direct costs of treating patients with schizophrenia, it is a staggering number: $22 billion in the United States alone. As effective as many of them are, antipsychotic drugs are costly, and many have significant side effects. We detail the history of these medications on the following pages. Effective antipsychotics remain a critical avenue of research, and we also take a look at drug candidates in the pipeline.

Of course, drugs are not enough. Those with schizophrenia need intensive social supports. As Jeffrey Lieberman, chair of Columbia University's department of psychiatry, puts it in the last story in this section, recovering from schizophrenia is a bit like being rescued from an island years after being shipwrecked. "You've been away for a long time ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies